Dr. GPCR Podcast << Back to podcast list Dr. Richard Premont About Dr. Richard Premont "Dr. Premont obtained his B.S. in Biology and Chemistry at the California Institute of Technology in 1985, and M.Ph . and Ph.D. in Biomedical Sciences (Pharmacology) at Mount Sinai School of Medicine (City University of New York) in 1990 and 1992, working with Ravi Iyengar on regulation/desensitization of the liver glucagon receptor and glucagon-stimulated adenylyl cyclase system. In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert Lefkowitz and Marc Caron at Duke University. His initial project to identify and clone taste receptors was unsuccessful, but led to the identification of GRK5 and continued focus on GRKs (particularly GRKs 4,5,6) and arrestins as GPCR regulators and as mediators of distinct signaling pathways through partners including GIT1. In 1999, obtained an independent faculty position at Duke in Gastroenterology, where he remained until 2018 studying GPCRs and their signaling pathways in the liver and in liver disease. In 2018, he moved to Harrington Discovery Institute and Case Western Reserve University, where he studies GPCR regulation by S-nitrosylation. My research focus is on understanding how distinct cellular signaling pathways interact and are coordinated to produce integrated physiological responses, and how dysregulation of this coordination results in pathophysiology. For this, we have worked in three main areas: the regulation of G protein-coupled receptor signaling particularly by the G protein-coupled receptor kinase (GRK) – beta-arrestin system, the coordination of heterotrimeric G protein, small GTP-binding protein and protein kinase pathways by GIT/PIX scaffolding complexes during cellular signaling, and characterizing the role of protein S-nitrosylation as a signaling post-translational modification in mediating and regulating cellular signaling pathways, particularly in conjunction with better characterized signaling systems. In our work, we utilize methods including structural biology and proteomics, molecular biology and biochemical enzymology, primary and model cell culture, and transgenic, knockout, knock-in and conditional models of mouse physiology and behavior." Dr. Richard Premont on the web Google Scholar LinkedIn Dr. GPCR Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Robert J. Lefkowitz About this episode It was December 14th, 2020, 1:50 pm, when I turned on my laptop and signed into Zoom for my chat with Bob. Bob, who, you might ask? Well, it’s the one and only Robert J. Lefkowitz, M.D., 2012 Nobel Prize in Chemistry, which he shared with Dr. Brian Kobilka . Bob doesn’t really need an introduction since his reputation precedes him. Before we pressed record, I asked if I could call him Bob, and he answered that only his mom used to call him Robert, especially when she was upset with him. I then pressed record, and we chatted for almost 2h about Bob’s career, discoveries, difficulties (yes, he’s had some too), Nobel week, and his memoir that he just published in collaboration with Dr. Randy Hall. Bob is James B. Duke Professor of Medicine and Professor of Biochemistry, Chemistry, and Pathology at the Duke University Medical Center. He began his career in the late 1960s and has been an Investigator of the Howard Hughes Medical Institute since 1976. His legacy lies in the numerous discoveries he and his team made in the GPCR field and in all those who trained in his laboratory and went on to pursue stellar scientific careers. I very much enjoyed chatting with Bob, and I hope you’ll enjoy learning more about him as well. Dr. Robert J. Lefkowitz on the web A Funny Thing Happened on the Way to Stockholm: The Adrenaline-Fueled Adventures of an Accidental Scientist Duke University Wikipedia Nobel Prize HHMI Lefkowitz Lab Google Scholar Pubmed Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Robert F. Bruns About Dr. Robert F. Bruns Fred Bruns discovered the first positive allosteric modulator (PAM) of a GPCR in the late 1980s while working at Warner-Lambert/Parke-Davis. The work was published in 1990. After 7 years at WL/PD and 26 years at Eli Lilly & Co., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced through Phase 2 clinical trials. Fred obtained an A.B. in Psychology from Washington University in St. Louis, followed by a Ph.D. in Neurosciences at the University of California, San Diego. His doctoral dissertation was the first large-scale study of structure-activity relationships for adenosine receptors. During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay. He then joined WL/PD, where his lab demonstrated the existence of two subtypes of the adenosine A2 receptor, A2a and A2b. In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab. He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997 switched to computational chemistry full-time. He supported the D1 PAM project in various roles from its inception in 2002 until selection of a clinical candidate in 2013. Dr. Bruns has over 80 publications and 11,000 citations, with an h-index of 47. Dr. Robert F. Bruns on the web ResearchGate LinkedIn Dr. GPCR Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi About Dr. Nagarajan Vaidehi "Nagarajan Vaidehi, Ph.D., is professor and chair of the Department of Computational and Quantitative Medicine (DCQM) at the Beckman Research Institute of the City of Hope in Los Angeles, CA. She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr. Vaidehi received her Ph.D. in quantum chemistry from the Indian Institute of Technology in India, where she was honored with the Distinguished Alumni Award in 2016. Following her postdoctoral studies on protein dynamics simulation methods at University of Southern California, and at Caltech, she became the director of biomolecular simulations at the Materials and Process Simulation Center, Beckman Institute at Caltech. Dr. Vaidehi joined the Beckman Research Institute of the City of Hope in 2006 as a Professor and became chair of DCQM in 2018. She has advanced the use of computational methods to meet the challenges of designing therapeutics with lower off target effects. She is an internationally recognized biophysicist for her contributions in developing constrained molecular dynamics simulation methods with emphasis on application to G-protein coupled receptors and drug design." Dr. Nagarajan Vaidehi on the web City of Hope Google Scholar LinkedIn Dr. GPCR Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Dr. GPCR Community Presentation Breaking Barriers: My Journey from Mexico to the Heart of the Dr. GPCR Ecosystem and beyond About Monserrat Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled receptor Autoproteolysis-Inducing (GAIN) domain of Latrophilin 3 receptor under the mentorship of Dr. Antony Boucard. I am currently a postdoctoral researcher fellow in Dr. Kathleen Caron's laboratory at UNC. My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic endothelial cells (LECs), a cellular model with unique junction arrangements where aGPCRs are mainly unexplored. " Monserrat Avila Zozaya on the web LinkedIn Caron Lab Antony Boucard Lab Dr. GPCR < Previous Session Next Session >

Dr. GPCR Podcast << Back to podcast list Dr. Rosie Dawaliby About Dr. Rosie Dawaliby "I’m an expert in early-stage drug discovery, targeting membrane proteins, especially GPCR. I have 10 years of experience in the development and management of R&D projects and teams in the field of pharmacology, in prestigious academic laboratories as well as in biopharmaceutical companies in Europe and the United States. I hold a Ph.D. in Life Sciences from the University of Lausanne, Switzerland, Department of Biochemistry (2005-2009), where I started working on membranes and membrane protein biochemistry by studying membrane fusion and autophagy in yeast and mammalian cells. I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role of the lipidic environment on their structure and function during my post-doctoral work (2010-2015). This joint project between prof. Brian Kobilka's lab at Stanford University and the SFMB laboratory at the Université Libre de Bruxelles (ULB) resulted in the first systematic study of phospholipid's effect on GPCR conformation and function. In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases. I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences, and know-how from the different stages of my career. Before founding G.CLIPS biotech in June 2020. And since then, my incredible adventure as CEO of this fast-growing company started and is continuing." Dr. Rosie Dawaliby on the web LinkedIn Dr. GPCR Ecosystem G.CLIPS Biotech on the web Website LinkedIn Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

< GPCR News < GPCRs in Oncology and Immunology Chemokine N-terminal-derived peptides differentially regulate signaling by the receptors CCR1 and CCR5 Published date November 23, 2023 Abstract "Inflammatory chemokines are often elevated in disease settings, where the largest group of CC-chemokines are the macrophage inflammatory proteins (MIP), which are promiscuous for the receptors CCR1 and CCR5. MIP chemokines, such as CCL3 and CCL5 are processed at the N-terminus, which influences signaling in a highly diverse manner. Here, we investigate the signaling capacity of peptides corresponding to truncated N-termini. These 3 to 10-residue peptides displayed weak potency but, surprisingly, retained their signaling on CCR1. In contrast, none of the peptides generated a signal on CCR5, but a CCL3-derived tetrapeptide was a positive modulator boosting the signal of several chemokine variants on CCR5. In conclusion, chemokine N-termini can be mimicked to produce small CCR1-selective agonists, as well as CCR5-selective modulators." Authors Olav Larsen , Sara Schuermans , Anna Walser , Stavroula Louka , Ida Aaberg Lillethorup , Jon Våbenø , Katrine Qvortrup , Paul Proost , Mette M Rosenkilde Tags GPCR , allosteric modulation , chemokine , chemokine truncation , pharmacology Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers GPCR Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology Structural and molecular insights into GPCR function GPCR Activation and Signaling More from Dr. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr. GPCR Monthly Newsletter today! Follow the Dr. GPCR News and get weekly notifications about the GPCR field Share < Previous Next >

Dr. GPCR Podcast << Back to podcast list Dr. Maria Waldhoer About this episode Dr. Maria Waldhoer is originally from Austria. She earned her M.Sc. in Zoology and Neurobiology before completing a Ph.D. in Biology and Pharmacology at the University of Vienna. GPCRs led Maria to Thue W. Schwartz’s lab in Copenhagen where she completed her postdoctoral training. After working in the US and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer. Even though Maria stumbled upon the GPCR field, her 20 years in both academia and in the industry working on GPCRs make her a strong and dedicated scientific leader. Dr. Maria Waldhoer on the web LinkedIn InterAx Biotech Pubmed Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Nicholas Holliday About Dr. Nicholas Holliday After an undergraduate degree at the University of Cambridge, Nick carried out his Ph.D. at King’s College London, supported by an AJ Clark Ph.D. studentship from the British Pharmacological Society. It was these studies and subsequent postdoctoral work that led to Nick's interest in peptide messengers regulating appetite, metabolism, and the immune system, and the molecular mechanisms underlying the signaling and regulation of their GPCRs. Nick joined the University of Nottingham in 2006, where he is now Associate Professor, establishing a lab focused on G protein-coupled receptor kinetics, signaling, and trafficking and on using novel imaging techniques, such as fluorescent ligands and complementation methods, to investigate the underlying mechanisms. Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief Scientific Officer, a contract research organization specializing in molecular and cellular pharmacology. Excellerate is involved in several pre-clinical drug discovery projects for both GPCR and non-GPCR targets, using its expertise in pharmacology to deliver high-quality target validation, lead optimization, and mechanism of action studies for our clients. Dr. Nicholas Holliday on the web LinkedIn ORCID University of Nottingham Twitter Excellerate Bio Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Jean Martin Beaulieu About Dr. Jean Martin Beaulieu Dr. Beaulieu received a Ph.D. in Neurological Sciences from McGill University and completed his post-doctoral training at Duke University. Prior to his recruitment Dr. Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience at Laval University. Dr. Beaulieu’s research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for mental illnesses such as schizophrenia, depression, and bipolar disorder. Dr. Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development. In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia and bipolar disorders. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug classes can engage overlapping cellular mechanisms to exert their action. The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents. Translational validation is important to validate findings obtained from experimental models research and bridge the gap between bench and bedside. Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk factors implicated in schizophrenia by large whole-genome association studies (GWAS) in humans. These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the regulation of protein synthesis as a potential downstream effector of the action of mood stabilizers and other psychoactive drugs. In addition to basic research, the Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology. Dr. Jean Martin Beaulieu on the web University of Toronto Google Scholar LinkedIn ResearchGate Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

< GPCR News < GPCRs in Oncology and Immunology LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration Published date September 25, 2023 Abstract "Background: G protein-coupled receptor heteromerization is believed to exert dynamic regulatory impact on signal transduction. CXC chemokine receptor 4 (CXCR4) and its ligand CXCL12, both of which are overexpressed in many cancers, play a pivotal role in metastasis. Likewise, lysophosphatidic acid receptor 1 (LPA1) is implicated in cancer cell proliferation and migration. In our preliminary study, we identified LPA1 as a prospective CXCR4 interactor. In the present study, we investigated in detail the formation of the CXCR4-LPA1 heteromer and characterized the unique molecular features and function of this heteromer. Methods: We employed bimolecular fluorescence complementation, bioluminescence resonance energy transfer, and proximity ligation assays to demonstrate heteromerization between CXCR4 and LPA1. To elucidate the distinctive molecular characteristics and functional implications of the CXCR4-LPA1 heteromer, we performed various assays, including cAMP, BRET for G protein activation, β-arrestin recruitment, ligand binding, and transwell migration assays. Results: We observed that CXCR4 forms heteromers with LPA1 in recombinant HEK293A cells and the human breast cancer cell line MDA-MB-231. Coexpression of LPA1 with CXCR4 reduced CXCL12-mediated cAMP inhibition, ERK activation, Gαi/o activation, and β-arrestin recruitment, while CXCL12 binding to CXCR4 remained unaffected. In contrast, CXCR4 had no impact on LPA1-mediated signaling. The addition of lysophosphatidic acid (LPA) further hindered CXCL12-induced Gαi/o recruitment to CXCR4. LPA or alkyl-OMPT inhibited CXCL12-induced migration in various cancer cells that endogenously express both CXCR4 and LPA1. Conversely, CXCL12-induced calcium signaling and migration were increased in LPAR1 knockout cells, and LPA1-selective antagonists enhanced CXCL12-induced Gαi/o signaling and cell migration in the parental MDA-MB-231 cells but not in LPA1-deficient cells. Ultimately, complete inhibition of cell migration toward CXCL12 and alkyl-OMPT was only achieved in the presence of both CXCR4 and LPA1 antagonists. Conclusions: The presence and impact of CXCR4-LPA1 heteromers on CXCL12-induced signaling and cell migration have been evidenced across various cell lines. This discovery provides crucial insights into a valuable regulatory mechanism of CXCR4 through heteromerization. Moreover, our findings propose a therapeutic potential in combined CXCR4 and LPA1 inhibitors for cancer and inflammatory diseases associated with these receptors, simultaneously raising concerns about the use of LPA1 antagonists alone for such conditions. Video Abstract." Authors Jong Min Hong , Jin-Woo Lee , Dong-Seung Seen , Jae-Yeon Jeong , Won-Ki Huh Tags Cancer , Chemokine receptor 4 , Chemotaxis , G protein-coupled receptor , GPCR heteromer , GPCR signaling , Inflammatory disease , Lysophosphatidic acid receptor 1 Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers GPCR Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology Structural and molecular insights into GPCR function GPCR Activation and Signaling More from Dr. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr. GPCR Monthly Newsletter today! Follow the Dr. GPCR News and get weekly notifications about the GPCR field Share < Previous Next >

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Unveiling Non-Canonical Functions for Gαq Signaling Pathways Date & Time Friday, November 3rd / 11:55 AM About Catalina Ribas " Dr. Catalina Ribas, is currently an Associate Professor at the University Autonomous of Madrid (UAM) and she has been Academic Secretary of Molecular Biology Department for several years. The research group led by Dr. Catalina Ribas, located in the Centro de Biología Molecular “Severo Ochoa” (UAM/CSIC) and belongs also to the Health Research Institute La Princesa, has extensive experience in the field of GPCR. Dr. Catalina Ribas made a postdoctoral stay in the laboratory of Dr. SM. Lanier in the MUSC (USA). During this period and her doctoral thesis, she has deepened the regulatory mechanisms of GPCR signaling. In her postdoctoral period, she has participated in the identification and characterization of proteins that act at the level of G proteins and which are part of a multimolecular signaling complex (AGS, de “Activators of G-protein signaling). In Spain, Dr. Ribas continued working on the regulation of GPCR. The group of Dr. Ribas has characterized the existence of a new signaling pathway with a relevant role in cardiac hypertrophy led by a new Gαq interactome. Recently, Dr. Ribas' group has described a new interaction region in a cellular protein that has turned out to be very relevant in the control of the cellular process known as autophagy. These results have been published in the journal Nature Communications (12 (1):4540, 2021) with the title "Gαq controls autophagy via modulation of the mTORC1 signaling hub". Furthermore, Dr. Ribas has also described a new protective role of G protein-coupled receptor kinase 2 (GRK2), a known regulator of Gq-GPCR signaling in HNSCC tumor progression (International Journal of Cancer, 2020). " Catalina Ribas on the web Severo Ochoa Molecular Biology Center X (Twitter) Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Dr. GPCR Podcast << Back to podcast list Dr. Terry Hébert About this episode Dr. Terry Hébert wanted to be a microbiologist. Instead, he ended up getting interested in membrane protein as he followed the biology of a bacterial toxin that affects a mammalian ion channel. Today he and his team are working on understanding receptor signaling in specialized cellular environments to gain a better grasp of receptor function in pathophysiological settings with a special interest in the cardiovascular system. His favorite GPCR is the angiotensin 1 receptor, especially for its ability to activate a large variety of signaling pathways. Terry is also very active on social media. With over 2000 followers on Facebook and Twitter, he shares the latest available information on GPCR research daily. Dr. Terry Hébert on the web Institute of Health Sciences Education Hébert Lab LinkedIn Facebook GPCR Consortium PubMed Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VII Physiological and pathological roles of AGPCRs in the nervous system Uncovering the signaling pathway of the ADGRA homolog Remoulade in Drosophila Beatriz Blanco Redondo The Adhesion GPCR Latrophilin Interacts With The Notch Pathway To Control Germ Cell Proliferation Willem Berend Post Uncovering the signaling pathway of the ADGRA homolog Remoulade in Drosophila Beatriz Blanco Redondo Abstract "The Drosophila genome contains five loci encoding adhesion G-protein coupled receptors (aGPCRs). Phylogenetic analysis revealed that the remoulade (remo) gene is a homologue of the vertebrate aGPCR ADGRA family, sharing the same overall receptor domain structure. In vivo expression profiling has shown Remo expression in the central (CNS) and peripheral nervous systems (PNS) of third-instar larvae (L3) and adults. In L3 PNS specimen Remo is expressed in a subset of neurons expressing the DEG/ENaC channel pickpocket (PPK), which is involved in transduction of sensory information like nociception. remoKO larvae and animals, in which remo was knocked down in ppk-neurons through RNA interference, show a higher nocifensive response compared to wildtype remorescue controls indicating that remo is required in PPK-neurons for this behaviour. Furthermore, with the aim to analyse the biochemical properties of Remo, we performed immunoprecipitation analysis. We found that the receptor is cleaved despite the lack of a consensus GPS sequence. Hence, Remo is proteolytically processed, either by the GAIN domain or an alternative protease that cleaved Remo near the GPS. We also aimed at identifying the signaling pathway that Remo is involved in. The mammalian Remo homolog ADGRA2/Gpr124 cooperates with other GPCRs of the Frizzled family, and the transmembrane proteins RECK and Lrp5/6. Collectively these proteins form a cell surface complex that acts as a recognition platform for Wnt ligands. Knowledge of the structural dynamics of this complex is limited and pharmacological and in vivo systems that would allow its characterization are scarce. Remo may serve a role in this peculiar signaling pathway and require further analysis." Authors & Affiliations "Auger, Genevieve Marie1, Bigl, Marina1, America, Michelle2, Vanhollebeke Benoit2, Langenhan Tobias1 1Rudolf Schönheimer Institute of Biochemistry, Division of General Biochemistry, Medical Faculty, Leipzig University, Johannisallee 30, 04103 Leipzig, Germany 2Laboratory of Neurovascular Signaling, Department of Molecular Biology, ULB Neuroscience Institute, Université libre de Bruxelles (ULB), Gosselies B-6041, Belgium" About Beatriz Blanco Redondo "I studied Biomedicine at the University of Barcelona. After my bachelors, I moved to Germany where I obtained my Master’s of Science and PhD degree in Dr. Buchner’s group at the University of Wuerzburg. Shortly after receiving my PhD, I joined Dr. Neil Shneider’s group as a postdoctoral research scientist at Columbia University, New York, where I studied the mechanisms of motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS). In 2017, I joined the group of Prof. Langenhan where I am studying and characterizing newly generated adhesion GPCR receptors in Drosophila as a model organism for future pharmacological applications." Beatriz Blanco Redondo on the web Blanco-Redondo Lab LinkedIn Google Scholar X (Twitter) The Adhesion GPCR Latrophilin Interacts With The Notch Pathway To Control Germ Cell Proliferation Willem Berend Post Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Groß Victoria Elisabeth 1, Matúš Daniel 2,3, Kaiser Anette 4, Ließmann Fabian 5, Meiler Jens 5, Schöneberg Torsten 2,6, Prömel Simone 1 1 Institute of Cell Biology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany 2 Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany 3 Department of Molecular and Cellular Physiology, Stanford University, Stanford CA, USA 4 Department of Anaesthesiology and Intensive Care, Medical Faculty, Leipzig University, Leipzig, Germany 5 Institute for Drug Discovery, Faculty of Medicine, Leipzig University 6 School of Medicine, University of Global Health Equity, Kigali, Rwanda" About Willem Berend Post "Willem Berend Post is a PhD student in Cell Biology at Heinrich Heine University in Düsseldorf, Germany. His research focuses on the relevance of aGPCRs in physiology and signaling using both in vitro and in vivo approaches." Willem Berend Post on the web Cell Biology LinkedIn < Previous Session Next Session >

Dr. GPCR Podcast << Back to podcast list Dr. Graeme Milligan About Dr. Graeme Milligan Professor Graeme Milligan is Gardiner Professor of Biochemistry, Dean of Research, and Deputy Head of the College of Medical, Veterinary, and Life Sciences at the University of Glasgow. His main research group centers on the function, structure, and regulation of G protein-coupled receptors (GPCRs) and their interacting proteins. His experience also includes translating knowledge generated into the selection of targets, screening, and identification of small molecule regulators of these proteins, and progressing such ligands in drug development programs. Prof. Milligan has published more than 550 peer-reviewed articles and his research has been cited more than 35,000 times. He was elected to the Fellowship of the Royal Society of Edinburgh in 1998 and to the Fellowship of the Academy of Medical Sciences in 2016. Prof. Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria. Dr. Graeme Milligan on the web University of Glasgow ResearchGate PubMed Orcid Google Scholar LinkedIn Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Patrick Sexton About Dr. Patrick Sexton Patrick Sexton is a Professor of Pharmacology, National Health and Medical Research Council of Australia Senior Principal Research Fellow, and Director of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins ( www.ccemmp.org ). He is a leader in the study of GPCRs, biased agonism, and also on allosteric interactions between GPCRs and other proteins and small molecule ligands. More recently, his team has been at the forefront of the application of cryo-EM to elucidate of the structure and dynamics of GPCRs. Prof. Sexton has published over 320 peer-reviewed journal articles and has been cited >26,000 times (Google Scholar). He is a 2021 Clarivate Analytics Highly Cited Researcher in two disciplines: Pharmacology & Toxicology and Biology & Biochemistry, a corresponding member of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification, and a member of the Faculty of 1000 (Molecular Pharmacology division) and an elected Fellow of the British Pharmacological Society (BPS). Prof. Sexton’s awards include the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Lecturer award, Endocrine Society of Australia Senior Plenary award, Rand Medal (ASCEPT), Paxinos-Watson Award (Australian Neuroscience Society), Vane Medal (BPS), Gordon Hammes Lectureship Award (American Chemical Society) and the GSK Research Excellence award. Prof. Sexton is also a co-founder of the San Francisco-based biotechnology company Septerna Inc . Dr. Patrick Sexton on the web CCeMMP Monash University Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Mark Connor ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Leaving for City Center Coming Soon < Previous Session Next Session >

< GPCR News < GPCRs in Oncology and Immunology Identification of a G-protein coupled receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis Published date June 18, 2024 Abstract " Background: Ovarian cancer (OV) is a common malignant tumor of the female reproductive system with a 5-year survival rate of ∼30 %. Inefficient early diagnosis and prognosis leads to poor survival in most patients. G protein-coupled receptors (GPCRs, the largest family of human cell surface receptors) are associated with OV. We aimed to identify GPCR-related gene (GPCRRG) signatures and develop a novel model to predict OV prognosis. Method: We downloaded data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Prognostic GPCRRGs were screened using least absolute shrinkage and selection operator (LASSO) Cox regression analysis, and a prognostic model was constructed. The predictive ability of the model was evaluated by Kaplan-Meier (K-M) survival analysis. The levels of GPCRRGs were examined in normal and OV cell lines using quantitative reverse-Etranscription polymerase chain reaction. The immunological characteristics of the high- and low-risk groups were analyzed using single-sample gene set enrichment analysis (ssGSEA) and CIBERSORT. Results: Based on the risks scores, 17 GPCRRGs were associated with OV prognosis. CXCR4, GPR34, LGR6, LPAR3, and RGS2 were significantly expressed in three OV datasets and enabled accurate OV diagnosis. K-M analysis of the prognostic model showed that it could differentiate high- and low-risk patients, which correspond to poorer and better prognoses, respectively. GPCRRG expression was correlated with immune infiltration rates. Conclusions: Our prognostic model elaborates on the roles of GPCRRGs in OV and provides a new tool for prognosis and immune response prediction in patients with OV." Authors Shaohan Ma, Ruyue Li, Guangqi Li, Meng Wei, Bowei Li, Yongmei Li, Chunfang Ha Tags G protein-coupled receptor , Immune infiltration , Molecular marker , Ovarian cancer , Prognostic model , epithelial Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers GPCR Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology Structural and molecular insights into GPCR function GPCR Activation and Signaling More from Dr. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr. GPCR Monthly Newsletter today! Follow the Dr. GPCR News and get weekly notifications about the GPCR field Share < Previous Next >

Trademark Policy FindYooour, LLC (“FindYooour”) provides its Service to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com, DrGPCR.com. If Dr. GPCR approves your request to use any Dr. GPCR trademarks, logos, web pages, screenshots, or other distinctive features ("Dr. GPCR Brand"), you agree to be bound by the following terms and conditions (the "Agreement"). ​ You agree to comply with the Guidelines for Third-Party Use of Dr. GPCR Brand Features. So long as you do so, and provided that Dr. GPCR expressly approves your permission request, Dr. GPCR grants you a non-transferable, non-exclusive, royalty-free limited license to use the Dr. GPCR Brand Features set forth in your corresponding Permission Request Form for the sole purpose and only for the materials set forth therein. Any use of the Dr. GPCR Brand Features must be accompanied by a notice that clearly indicates that the Dr. GPCR Brand Features are trademarks or distinctive brand features of FindYooour LLC. Dr. GPCR reserves the right in its sole discretion to terminate or modify your permission to display the Dr. GPCR Brand Features and to take action against any use that does not conform to these terms and conditions, infringes any intellectual property or other rights or violates applicable law. Except as set forth above, nothing herein grants or should be deemed to grant to you any right, title, or interest in or to the Dr. GPCR Brand Features. Your use of the Dr. GPCR Brand Features will inure to the benefit of Dr. GPCR. You agree not to challenge or assist others to challenge the Dr. GPCR Brand Features (except to the extent such restriction is prohibited by applicable law), and you agree not to register or attempt to register any domain names, trademarks, trade names, or other distinctive brand features that are confusingly similar to those of Dr. GPCR. The Dr. GPCR Brand Features are provided "as is" and Dr. GPCR disclaims any warranties either expressed or implied by law regarding the Dr. GPCR Brand Features, including warranties of non-infringement. Furthermore, because you are not being charged for use of the Dr. GPCR Brand Features, in no event shall Dr. GPCR be liable to you for the subject matter of this Agreement under any theory of liability including for any direct, indirect, incidental, special, consequential, punitive, exemplary or other damages arising out of this Agreement or the use of the Dr. GPCR Brand Features. This limitation shall apply even if Dr. GPCR was or should have been aware or advised of the possibility of such damages and notwithstanding any failure of essential purpose of any limited remedy stated herein. Some states do not allow the exclusion of implied warranties or limitation of liability for incidental or consequential damages, so the above limitations or exclusions may not apply to you. You may not assign your rights or delegate your obligations under this Agreement without Dr. GPCR's prior written consent. This Agreement is not intended to benefit, nor shall it be deemed to give rise to, any rights in any third party. These Terms and Conditions shall be governed by the laws of the State of New York without regard to the principles of conflicts of law. Unless otherwise elected by Dr. GPCR in a particular instance, Customer hereby expressly agrees to submit to the exclusive personal jurisdiction of the federal and state courts of New York County, New York. The parties are independent contractors. Neither party shall be deemed to be an employee, agent, partner, or legal representative of the other for any purpose and neither shall have any right, power, or authority to create any obligation or responsibility on behalf of the other. The waiver by FindYooour, LLC of a breach of any provision hereof shall not be taken or held to be a waiver of the provision itself. If any provision of this Agreement is held by a court of competent jurisdiction to be contrary to law, such provision shall be changed and interpreted so as to best accomplish the objectives of the original provision to the fullest extent allowed by law and the remaining provisions of this Agreement shall remain in full force and effect. This Agreement, the Guidelines for Third-Party Use of Dr. GPCR Brand Features, and the Permission Request Form constitute the entire agreement between the parties with respect to the subject matter hereof. If you’ve found a website that uses a Dr. GPCR trademark inappropriately, we’d like to hear about it. Report inappropriate use of a D. GPCR trademark. Buttons And Badges The Dr. GPCR buttons and badges are publisher integration points that applications, websites, and other services (collectively, "Publishers") can add to websites so that Dr. GPCR users can connect to and share on Dr. GPCR. These include: - Dr. GPCR Badge and Follow button This button is a means for Publishers to enable Dr. GPCR users to quickly follow the Publisher's Business Page directly via a widget on the Publisher's website. After clicking the button, the user indicates to follow that Publisher. - Dr. GPCR Share button The share buttons provide a lightweight way for Publishers to invoke a Dr. GPCR Share dialog and can be implemented using a Dr. GPCR icon. The policies below, as well as the Dr. GPCR Buttons and Badges guidelines, the Dr. GPCR Terms of Service, govern a Publisher's use of the Dr. GPCR buttons. Buttons And Badges Policy ​ Publishers may not attempt to discover the identity of a Dr. GPCR button user unless the user consents to share his or her identity with the Publisher via a Dr. GPCR-approved authorization procedure. This prohibition includes identifying users by correlating Dr. GPCR button reporting data from Dr. GPCR with Publisher data. Publishers may not sell or transmit to others any data about a user related to the user's use of any Dr. GPCR button. For the avoidance of doubt, this prohibition includes, but is not limited to, any use of pixels, cookies, or other methods to recognize users' clicks on a Dr. GPCR button, the data of which is then disclosed, sold, or otherwise shared with other parties. Publishers must disclose clearly any data collection, sharing, and usage that takes place on any site, app, or other property as a consequence of using Dr. GPCR buttons. To comply with this disclosure obligation with respect to Dr. GPCR's use of data, publishers have the option to display a prominent link to How Dr. GPCR uses data when you use our partners’ sites or apps. Publishers may not alter or obfuscate a Dr. GPCR button, and Publishers may not associate a Dr. GPCR button with advertising content, such as putting the Dr. GPCR Button on or adjacent to an ad, or placing ads in shared content, unless authorized to do so by Dr. GPPCR. Publishers also may not place in shared content any text, image, or other content that violates the Dr. GPCR User Content and Conduct Policy . For buttons that may be rendered by the Publisher, such as the Sharing link, the Publisher must use only the official Dr. GPCR-provided icon or a plain text and link combination. In either case, Publishers must not mislead users as to the purpose of the link. Publishers may not direct users to click a Dr. GPCR button for purposes of misleading users. Publishers may not promote prizes, monies, or monetary equivalents in exchange for Dr. GPCR button clicks. For the avoidance of doubt, Publishers may direct users to a Dr. GPCR button to enable content and functionality. When a Publisher directs users to a Dr. GPCR Button, the button action must be related to the Publisher or the Publisher's content. For the Share button, the content or functionality that is enabled for the user must also be accessible to any of the user's social connections who also enable it. FindYooour may analyze Publishers' use of a Dr. GPCR button including to ensure Publishers' compliance with these policies and to facilitate Dr. GPCR development of Dr. GPCR Buttons. By using a Dr. GPCR button, Publishers give Dr. GPCR permission to utilize an automated software program, often called a "web crawler," to retrieve and analyze websites associated with a Dr. GPCR button. If Publishers' sites or services are directed at children under 13 or Publishers have actual knowledge that users of their site or service are children under 13, then Publishers must comply with the US Children's Online Privacy Protection Act when using any Dr. GPCR buttons. ​ Buttons And Badges Guideline ​ These guidelines provide you with the design specification for various Dr. GPCR buttons and badges. You can use these assets on your app (website or mobile app) without pre-approval provided you follow these basic guidelines. Use of Dr. GPCR brands in ways not expressly covered by this document is not allowed without prior written consent from Dr. GPCR. Button use must also be in line with this Button's Policy. ​ Dr. GPCR badge, share and follow button branding guidelines ​ Adding a Dr. GPCR badge to your website, email, or marketing campaign makes it easy for fans to follow you, or join your community. Similarly, the compact. The Share button allows visitors to easily share your content with their circles. We prefer that you use the MagyarBusiness.org badge, Share button, and Follow button in their provided formats. ​ Dr. GPCR icon as a button or badge: ​ In certain situations, you might want to use the Dr. GPCR icon to enable users to share content to Dr. GPCR or to link to your Page so that users can follow you. You can do this so long as the context makes it clear what action will be taken when the user clicks on the icon. In addition, the icon must adhere to the Dr. GPCR icon guidelines below, including color scheme, styling, and so forth. ​ Dr. GPCR Brand Permissions ​ All of our brand features are protected by applicable trademark, copyright and other intellectual property laws. If you would like to use any of our brand features on your website, in an ad, in an article or book, or reproduce them anywhere else, or in any other medium, you'll need to receive permission from Dr. GPCR first. And please note that the user experience with all our products should never be altered. Using Dr. GPCR logo ​ The Dr. GPCR logo is the most prominent visual representation of our brand, and we want it to be used in the right way. We generally do not approve the use of our logo in third-party marketing materials. This includes online and offline advertising collateral such as: Merchandise featuring the Dr. GPCR logo ​ We cannot grant permission for the use of Dr. GPCR Logo in different marketing materials, such as: a new T-shirt design, a toy, software packaging, or other products. Screenshots of Dr. GPCR products ​ You don't need our permission when you want to use an unaltered screenshot of our Website (DrGPCR.com or Ecosystem.DrGPCR.com) or the search results page for instructional or illustrative purposes. This applies for print (book, magazine, journal, newspaper) or digital (webpage, DVD, CD, post) formats. Please see below for exceptions to this rule for some of our other products. Don’t use unaltered screenshots about the Dr. GPCR Websites. When we say "unaltered", we mean no superimposed graphics, photos, or ad copy on the screenshot and no changes to the way our product looks. We also don't give permission for advertisers to use Dr. GPCR pages in connection with advertising products or services (for instance, showing a top ranking on Dr. GPCR search result page). We ask that you put the following tagline beneath any image featuring a Dr. GPCR product screenshot or data: Note: Dr. GPCR and the Dr. GPCR logo are registered trademarks of FindYooour LLC., used with permission. Use of trademarks ​ Our trademarks are our valuable assets, and we want to make sure our users and partners use them correctly. These trademarks include the Logo, Buttons, Badges, Website Design and other pictures and graphic designs owned and created by Dr. GPCR How to use You may use our trademarks to accurately refer to our products or services, as long as such references are appropriate and consistent with our trademark guidelines. You may use only approved versions of our marks. Please follow all of the general trademark. The trademark usage guidelines apply even to marks that were previously (but are no longer) used in connection with our products. ​ How not to use ​ You may not use, incorporate or combine any of our trademarks into a third-party brand name, product name, business name, trade name or slogan. You may not use any of our marks in a way that suggests you are endorsed by or affiliated with Dr. GPCR or our products. For example, you may not use our marks: - in domain names - as app icons or featured in an app - as the most prominent elements on your website - on physical merchandise, promotional materials, business cards or business stationery - in product reviews Please do not modify or mimic our marks.

Dr. GPCR Podcast << Back to podcast list Dr. Kaavya Krishna Kumar About Dr. Kaavya Krishna Kumar "I am a postdoc in Prof. Brian Kobilka's lab at Stanford University, USA. I work on understanding the activation mechanism of different Families of GPCRs." Dr. Kaavya Krishna Kumar on the web Journal of Biology Chemistry Stanford University Google Scholar LinkedIn Dr. GPCR Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 1 Date & Time Thursday, November 2nd / 2:45 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Dr. GPCR Podcast << Back to podcast list Dr. Michael Feigin About Dr. Michael Feigin "Dr. Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo, NY. He earned his Ph.D. under Dr. Craig Malbon at SUNY Stony Brook studying the role of G-protein coupled receptors (GPCRs) and their regulators in the Wnt signaling pathway. Mike then joined the lab of Dr. Senthil Muthuswamy at Cold Spring Harbor Laboratory and probed the roles of polarity proteins (Feigin, et al., Cancer Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models, three-dimensional cell culture and computational approaches to drug target discovery. When Dr. Muthuswamy moved to the University of Toronto, Mike joined the laboratory of Dr. David Tuveson at CSHL where he participated in the development of an organoid system for the culture of normal and malignant pancreatic tissue, allowing advances in sequencing, target discovery and biomarker development. He also continued his interest in computational analysis of cancer drivers by co-developing GECCO, an algorithm for the identification of noncoding mutations driving gene expression in pancreatic cancer (Feigin and Garvin, et al., Nature Genetics, 2017). Mike's lab has two main areas of interest: 1) alternative polyadenylation as a targetable driver of pancreatic cancer, and 2) dysregulation of the pancreatic tumor microenvironment by commonly prescribed anti-anxiety drugs." Dr. Michael Feigin on the web Roswell Park Feigin Lab Google Scholar LinkedIn Twitter Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap Yamina and Mike engaged in a conversation about their scientific research experiences. Mike shared his journey from his Ph.D. struggles to his current role as a professor, emphasizing the importance of resilience and creativity. They also discussed his research on cell polarity and its role in cancer progression, his work on G-protein coupled receptors (GPCRs) in breast cancer, and his interest in pancreatic cancer. The discussion also covered the challenges they face in studying GPCRs due to their low expression levels and the difficulty of localizing these receptors in tissues. Next steps • Mike will consider using Twitter to post job positions in his lab. Summary Science Roles and Resilience Yamina and Mike had a conversation about their roles and experiences in the field of science. Yamina introduced herself and Mike shared his educational background and his journey to becoming a professor. Mike also spoke about his initial struggles during his Ph.D., such as a difficult model system and a lack of experimental results. He explained that he overcame these challenges by reading extensively and contemplating alternative plans. The conversation also highlighted the importance of resilience and creativity in scientific research. Science Journey and Postdoc Decision Mike discussed his journey into science and his decision to pursue a postdoc at Cold Spring Harbor. He shared that his interest in science originated from a young age and his desire to gain more knowledge about cancer biology led him to transition into using mouse models. Yamina asked about his move from in vitro to in vivo work, and Mike explained that he wanted to use better models to understand cancer signaling pathways. They also shared their personal experiences and interest in the field of biology. Towards the end, Mike mentioned that he stayed at Cold Spring Harbor even after his mentor left for Toronto. Mike's Research on Cell Polarity and GPCRs in Cancer Mike shared his research on cell polarity and its role in cancer progression, particularly focusing on the potential of disrupted cell polarity as a driver of tumorigenesis. He also discussed his work on G-protein coupled receptors (GPCRs) in breast cancer, identifying GPR161 as a potential drug target due to its high expression in triple negative breast cancer. Mike then transitioned to pancreatic cancer, questioning why genes are dysregulated in cancer, which led him to explore different aspects of gene regulation and its relation to cancer progression. Yamina acknowledged the difficulty in identifying GPCRs expressed in cancer cells but not in normal ones, and commended Mike's innovative approach to the question. Career Trajectory and Faculty Position Yamina and Mike discussed Mike's career trajectory and his decision to pursue a faculty position. Mike expressed his initial reluctance due to a lack of confidence and fear of not being ready. However, he decided to undertake another postdoc to gain more experience and confidence. He also highlighted the importance of publishing strong papers and having a clear vision for his lab. Yamina emphasized the importance of thorough preparation and planning before applying for faculty positions. They also discussed the challenges of the two-body problem, where both partners need to find suitable positions. Mike shared his strategy of developing preliminary projects and gathering data to strengthen his application. Teamwork and Flexibility in Scientific Research Mike shared about his recent promotion and the way he has managed his team, encouraging them to come up with their own ideas and then guiding them. Yamina congratulated Mike on his promotion and discussed the importance of flexibility in scientific research, even when starting with a clear plan. Mike also mentioned how his team collaborates closely, with weekly roundtable discussions where everyone shares their progress and issues. The conversation ended with Yamina expressing interest in learning more about Mike's two main research areas in his lab. GPCR Targeted Drugs and Gene Regulation in Cancer Cells Mike presented research on the effect of GPCR-targeted drugs on cancer-associated fibroblasts and discussed their work on gene regulation in fibroblasts. He highlighted their interest in non-coding mutations in promoters and the 3'UTR region important for gene regulation. Mike also shared about a drug that targets an enzyme involved in mRNA cleaving, which has been found to stop cancer cells from growing and invading. He also discussed the impact of disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic index for a drug called JTE-6.7. Yamina asked about the typical role of the enzyme and the challenges in delivering a molecule to target this enzyme and only cancer cells. Cytokine Inhibition, Collaboration, and Anti-Anxiety Drug Research Mike discussed the ongoing research on a drug that inhibits cytokine synthesis, its potential in killing cancer cells, and the team's efforts to understand its resistance mechanisms. He also touched upon a collaboration with Todd Ricky's group at UPenn to explore the GPCR side of the lab, which led to the discovery of potential tumor suppressors and oncogenes in melanoma. Furthermore, Mike mentioned a qualifying exam where students proposed new projects, highlighting Abby Cornwell's project on the effects of anti-anxiety drugs on pancreatic cancer patients, and the team's research on the potential issues with certain anti-anxiety drugs. The team found that these drugs could interact with GPR68, which is highly expressed in cancer-associated fibroblasts and is crucial for their function, leading to complications in cancer patients. The team is now examining other anti-anxiety drugs and common patient medications in the context of pancreatic cancer. GPCRs and Cancer Immune Modulation Yamina and Mike had a discussion about their research on GPCRs, specifically focusing on GPR68 and its role in the tumor microenvironment. They also touched upon the potential of GPCR modulation in stimulating the immune system to fight cancer. Mike shared his team's current focus on alprazolam, an anti-anxiety medication that has unexpected effects in the tumor microenvironment. They also discussed the challenges they face in studying GPCRs due to their low expression levels and the difficulty of localizing these receptors in tissues. Mike expressed a need for better tools to study GPCR localization in tissues. Scientific Journey and Drug Discovery Challenges Mike shared significant moments in his scientific journey, including the discovery of RGS proteins and its impact on his research approach. He also discussed his experiments and discoveries about GPR161 in mammary epithelial cells, the effect of alprazolam on tumors, and the potential dangers of drug interactions. Yamina proposed further exploration of dosage and length of treatment in a mouse model and suggested using a biosensor-based assay to examine dose-response curves. The conversation highlighted the complexities and challenges of drug prescription and the potential for alternative treatments. Science Journeys and Career Advice Yamina and Mike discussed their experiences in the field of science. Mike advised junior scientists to focus on projects they are passionate about, emphasizing that ownership and full investment in a project can make dealing with challenges easier. Yamina shared her personal journey, describing how she took her project in a different direction and felt a sense of ownership. Mike reflected on his early years as a postdoc, admitting that he lacked focus and didn't see the direct impact of his work on patients. He highlighted the importance of re-evaluating one's work and its potential implications. Towards the end, Yamina asked about job opportunities in Mike's lab, to which Mike responded that potential candidates can find him on Twitter. Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Katarzyna Marcinkiewicz About Dr. Katarzyna Marcinkiewicz "Katarzyna is a Senior Editor at Nature Communications, which she joined in April 2020, following three years on the editorial teams of Nature Structural and Molecular Biology and Nature Biotechnology. She obtained her Ph.D. from Weill Cornell Graduate School of Medical Sciences in New York City, studying epigenetic changes in cancer. During her postdoctoral training at New York University School of Medicine, her research focused on cellular senescence. Katarzyna handles submissions in structural biology, biophysics and biochemistry, with a particular focus on membrane proteins and protein folding." Dr. Katarzyna Marcinkiewicz on the web LinkedIn Nature The Spectator Dr. GPCR Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Randy Hall About Dr. Randy Hall Randy Hall, Ph.D., is a Professor of Pharmacology and Chemical Biology in the Emory University School of Medicine. Randy received his Bachelor's degree in 1990 from the University of New Hampshire and attended graduate school at the University of California at Irvine, studying the regulation of ionotropic glutamate receptors under the direction of Gary Lynch. After obtaining his Ph.D. in 1994, Randy moved to the Vollum Institute in Portland, Oregon, to do a post-doctoral fellowship in the laboratory of Thomas Soderling studying glutamate receptor trafficking and phosphorylation. In 1996, Randy continued his post-doctoral training at Duke University, where he studied the regulation of adrenergic receptors in the laboratory of Nobel Laureate Robert Lefkowitz . Randy then joined the faculty at the Emory University School of Medicine in 1999. Over the past two decades, his lab has published numerous groundbreaking findings shedding light on the signaling and regulation of GPCRs from the adrenergic, purinergic, glutamatergic, GABAergic, and adhesion sub-families. Most recently, his lab has made a number of seminal contributions to understanding the signaling, regulation and in vivo actions of the neuroprotective receptors GPR37 & GPR37L1 as well as the adhesion GPCRs BAI1, BAI2, and GPR56. Randy’s lab has a special interest in studying disease-associated mutations to human GPCRs that perturb receptor signaling and/or trafficking. Randy has received a number of research prizes, including the PhRMA New Investigator Award, the Distinguished Young Scholar in Medical Research Award from the W.M. Keck Foundation, and the John J. Abel Award from ASPET . In 2014, he was named a Fellow of the AAAS. In 2021, he co-authored the critically-acclaimed memoir of his mentor Bob Lefkowitz, entitled “A Funny Thing Happened on the Way to Stockholm: The Adrenaline-Fueled Adventures of an Accidental Scientist”. Join me to learn more about Randy’s work, hear his insights on the GPCR field, and also hear the story of how he came to co-author the memoir of his legendary mentor. Dr. Randy Hall on the web Hall Lab LinkedIn Google Scholar ResearchGate Dr. Lefkowitz Memoir. Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Brian Arey About this episode Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery and Optimization at Bristol-Myers Squibb Co . in Lawrenceville, NJ. He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing his postdoctoral training at Northwestern University. He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility. He currently leads a team that provides a mechanistic understanding of small molecule drug candidates across the entire portfolio of BMS. Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular, biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems. Dr. Arey’s laboratory discovered the first described synthetic agonists and antagonists of the FSHR and has been an early champion of signaling bias as a physiological mechanism of gonadotropin action. He continues to pioneer in drug discovery studying GPCRs and other target classes. His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics is available on Amazon . I sat down with Brian to chat about GPCRs, working in the industry, and being a leader. This is part 1 of our conversation. Dr. Brian Arey on the web LinkedIn ResearchGate Pubmed Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Françoise Bachelerie About Dr. Françoise Bachelerie " FB leads a team at Paris-Saclay University with expertise in immunology and virology related to Host/Virus interactions and GPCR function. The team’s projects are devoted to the activation/function of CXCR4-ACKR3 (CXCR7) receptors of the CXCL12 chemokine, key effectors of the immune system, including their role in immunological disorders (e.g. WHIM syndrome) and in the innate control of the life cycle of papillomavirus, which are commensal inhabiting the healthy human epithelium (virome) while presenting an oncogenic potential that remains a major health concern. FB is recognized for her expertise and pioneering works in the field of biological and pathological functions of chemokines and their receptors, for which she made important breakthroughs regarding the CXCL12/CXCR4/ACKR3 trio. In particular, FB contributed to the discovery that CXCL12 is the ligand for the CXCR4 receptor and can therefore prevent infection by the Human Immunodeficiency Virus (HIV). FB’ team has identified the orphan CXCR7/ACKR3 receptor as being the 2nd receptor for CXCL12, which behaves as a modulator of CXCL12/CXCR4 functions. FB is a member of various international committees in the field, including the one that reviewed the standard nomenclature for chemokine receptors that are categorized into a large subgroup of G protein–coupled (GPCR) leukocyte chemotactic receptors (including CXCR4), and a smaller subgroup of atypical chemokine receptors (including the CXCR7/ACKR3). " Dr. Françoise Bachelerie on the web INSERM ResearchGate SciSpace Loop LinkedIn Dr. GPCR Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice Date & Time Friday, November 3rd / 1:55 PM About Khaled Abdelrahman Dr. Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis underlying altered cerebrovascular function and blood flow in type 2 diabetes. In 2015, He joined Dr. Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at the University of Ottawa as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted pharmacologically to slow neurodegeneration. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases. He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral Fellowships offered by Alberta Innovates and Canadian Institutes of Health Research. He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics. Khaled Abdelrahman on the web University of British Columbia Twitter PubMed Google Scholar Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by